XOMA SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Xoma Corporation

NEW YORK--(BUSINESS WIRE)--

Levi & Korsinsky announces it has commenced an investigation of Xoma Corporation XOMA concerning possible violations of federal securities laws. The investigation concerns whether Xoma Corporation and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On July 22, 2015, XOMA announced that a Phase III trial of its treatment gevokizumab for Behcet's disease in the eye missed the primary endpoint of time to first acute ocular exacerbation. To obtain additional information, go to:

http://zlk.9nl.com/xoma

or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150723006143/en/